* asymptomatic person * inability to make a decision to participate (dementia, person under legal protection, curatorship or guardianship) * ongoing illness or chronic treatment contraindicated by taking one of the trial drugs.

* asymptomatic person * inability to make a decision to participate (dementia, person under legal protection, curatorship or guardianship) * ongoing illness or chronic treatment contraindicated by taking one of the trial drugs.

- asymptomatic person - inability to make a decision to participate (dementia, person under legal protection, curatorship or guardianship) - ongoing illness or chronic treatment contraindicated by taking one of the trial drugs.

- asymptomatic person - inability to make a decision to participate (dementia, person under legal protection, curatorship or guardianship) - ongoing illness or chronic treatment contraindicated by taking one of the trial drugs.

- inability to make a decision to participate (dementia, guardianship) - long qt syndrome, or qtc space > 500 ms - presence of a pace maker - heart rate <50 / min - hyperkalemia > 5.5 mmol/l or hypokalemia < 3.5 mmol/l - treatment with dasatinib, nilotinib, ibrutinib, potent inhibitors of cytochrome p450 cyp3a4 isoenzyme, potent inducers of cytochrome p450 cyp3a4 isoenzyme, warfarin - hypersensitivity to any of the trial drugs, ara2 or sartan. - liver failure (stage ≥ child-pugh b), stage 4 or 5 chronic kidney disease (dfg <30 ml/min/1.73 m²), person on dialysis, malabsorption syndrome, ileus, colitis or enterocolitis, chronic infection with the hepatitis b virus

- inability to make a decision to participate (dementia, guardianship) - long qt syndrome, or qtc space > 500 ms - presence of a pace maker - heart rate <50 / min - hyperkalemia > 5.5 mmol/l or hypokalemia < 3.5 mmol/l - treatment with dasatinib, nilotinib, ibrutinib, potent inhibitors of cytochrome p450 cyp3a4 isoenzyme, potent inducers of cytochrome p450 cyp3a4 isoenzyme, warfarin - hypersensitivity to any of the trial drugs, ara2 or sartan. - liver failure (stage ≥ child-pugh b), stage 4 or 5 chronic kidney disease (dfg <30 ml/min/1.73 m²), person on dialysis, malabsorption syndrome, ileus, colitis or enterocolitis, chronic infection with the hepatitis b virus